Telitacicept

Baocheng Liu1, Yaqi Zhao2, Dongxia Liu1

  • 1Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, People's Republic of China.

PubMed
概括

泰利塔西塞普是一种新的生物向B淋巴细胞激活因子 (BAFF) 和诱导增殖的配体 (APRIL) 的新型生物向药物,在SLE等自身免疫性疾病中显示出已证明的疗效和安全性. 进一步的研究将澄清最佳治疗时间.